Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)

Next Previous
Trial Profile

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prednisolone (Primary) ; Secukinumab (Primary) ; Vitamin D
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TitAIN
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 04 Jun 2022 Results assessing efficacy, safety, and tolerability of secukinumab in Giant Cell Arteritis patients, presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 09 Nov 2021 Results presented at the ACR Convergence 2021
    • 17 Aug 2021 Trial design published in the Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top